The Chemours Company (NYSE:CC – Get Rating) insider Alisha Bellezza sold 14,365 shares of the firm’s stock in a transaction on Thursday, May 5th. The stock was sold at an average price of $40.48, for a total value of $581,495.20. Following the sale, the insider now directly owns 38,797 shares of the company’s stock, valued at $1,570,502.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Chemours stock opened at $40.06 on Friday. The stock has a market cap of $6.23 billion, a PE ratio of 8.92, a price-to-earnings-growth ratio of 0.72 and a beta of 1.81. The business has a fifty day simple moving average of $31.52 and a 200-day simple moving average of $31.85. The company has a quick ratio of 1.21, a current ratio of 1.91 and a debt-to-equity ratio of 3.16. The Chemours Company has a 12 month low of $22.56 and a 12 month high of $42.00.
Chemours (NYSE:CC – Get Rating) last issued its earnings results on Monday, May 2nd. The specialty chemicals company reported $1.46 EPS for the quarter, topping the consensus estimate of $0.92 by $0.54. Chemours had a return on equity of 76.47% and a net margin of 11.19%. During the same period in the previous year, the firm earned $0.71 earnings per share. Analysts expect that The Chemours Company will post 4.84 EPS for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AdvisorNet Financial Inc boosted its position in Chemours by 63.2% during the first quarter. AdvisorNet Financial Inc now owns 785 shares of the specialty chemicals company’s stock valued at $25,000 after purchasing an additional 304 shares during the last quarter. Sageworth Trust Co of South Dakota bought a new position in Chemours during the fourth quarter valued at about $26,000. Clearstead Advisors LLC lifted its position in shares of Chemours by 666.7% in the third quarter. Clearstead Advisors LLC now owns 920 shares of the specialty chemicals company’s stock worth $27,000 after buying an additional 800 shares during the last quarter. Prospera Financial Services Inc bought a new stake in shares of Chemours during the 1st quarter worth about $29,000. Finally, Old North State Trust LLC increased its holdings in shares of Chemours by 58.7% during the 4th quarter. Old North State Trust LLC now owns 949 shares of the specialty chemicals company’s stock valued at $32,000 after acquiring an additional 351 shares during the last quarter. 76.38% of the stock is owned by hedge funds and other institutional investors.
CC has been the subject of several research reports. Royal Bank of Canada reduced their price objective on Chemours from $44.00 to $41.00 and set an “outperform” rating for the company in a research note on Tuesday, February 15th. JPMorgan Chase & Co. reduced their price objective on Chemours from $35.00 to $30.00 and set a “neutral” rating for the company in a research note on Monday, February 14th. Finally, StockNews.com raised Chemours from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $39.50.
About Chemours (Get Rating)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
- Get a free copy of the StockNews.com research report on Chemours (CC)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.